Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Bedke

Showing results (1-10 of 56) with videos related to

Pageof 6
Sort By:
Der Urologe. Ausg. A|May 28, 2020
[KEYNOTE-426 : Axitinib plus pembrolizumab vs sunitinib in the first-line treatment of metastatic renal cell carcinoma]J Bedke, V Stühler
Der Urologe. Ausg. A|September 3, 2010
[Renal cell carcinoma: recent developments in diagnostics and therapy]J Bedke, A Stenzl
Der Urologe. Ausg. A|March 2, 2017
[First-line therapy in advanced renal cell carcinoma : A randomized, open-label phase III study evaluating the efficacy and safety of pembrolizumab (MK-3475) in combination with axitinib compared to sunitinib monotherapy as first-line treatment for locally advanced or metastatic renal cell carcinoma (mRCC) (Keynote-426) - AN 39/16 of the AUO]H Rexer, J Bedke
Aktuelle Urologie|October 22, 2015
[Molecular Concepts of Immunomodulation for the Treatment of Metastatic Renal Cell Carcinomas: Where are We Now?]P J Goebell, J Bedke
Aktuelle Urologie|August 27, 2020
H Rexer, J Bedke, A Merseburger
Der Urologe. Ausg. A|October 13, 2011
[Prostate carcinoma: vaccination as a new option for treatment]J Bedke, C Gouttefangeas, A Stenzl
Aktuelle Urologie|February 5, 2020
H Rexer, J Bedke, F Imkamp
Der Urologe. Ausg. A|May 18, 2019
[Surgical reconstruction of the ureter]V Stühler, J Bedke, A Stenzl
Der Urologe. Ausg. A|June 16, 2017
[An open single-arm phase II monotherapy study of pembrolizumab (MK-3475) in locally advanced/metastatic renal cell carcinoma (mRCC) (Keynote 427) - AN 40/16 of the AUO]H Rexer, C Doehn, J Bedke
Der Urologe. Ausg. A|August 24, 2014
[Elective organ and function preservation in ureter and renal pelvis tumors]S Rausch, G Gakis, J Bedke, et al.
Pageof 6

Showing results (1-10 of 56) with videos related to

Sort By:
Pageof 6
Der Urologe. Ausg. A|May 28, 2020
[KEYNOTE-426 : Axitinib plus pembrolizumab vs sunitinib in the first-line treatment of metastatic renal cell carcinoma]J Bedke, V Stühler
Der Urologe. Ausg. A|September 3, 2010
[Renal cell carcinoma: recent developments in diagnostics and therapy]J Bedke, A Stenzl
Der Urologe. Ausg. A|March 2, 2017
[First-line therapy in advanced renal cell carcinoma : A randomized, open-label phase III study evaluating the efficacy and safety of pembrolizumab (MK-3475) in combination with axitinib compared to sunitinib monotherapy as first-line treatment for locally advanced or metastatic renal cell carcinoma (mRCC) (Keynote-426) - AN 39/16 of the AUO]H Rexer, J Bedke
Aktuelle Urologie|October 22, 2015
[Molecular Concepts of Immunomodulation for the Treatment of Metastatic Renal Cell Carcinomas: Where are We Now?]P J Goebell, J Bedke
Aktuelle Urologie|August 27, 2020
H Rexer, J Bedke, A Merseburger
Der Urologe. Ausg. A|October 13, 2011
[Prostate carcinoma: vaccination as a new option for treatment]J Bedke, C Gouttefangeas, A Stenzl
Aktuelle Urologie|February 5, 2020
H Rexer, J Bedke, F Imkamp
Der Urologe. Ausg. A|May 18, 2019
[Surgical reconstruction of the ureter]V Stühler, J Bedke, A Stenzl
Der Urologe. Ausg. A|June 16, 2017
[An open single-arm phase II monotherapy study of pembrolizumab (MK-3475) in locally advanced/metastatic renal cell carcinoma (mRCC) (Keynote 427) - AN 40/16 of the AUO]H Rexer, C Doehn, J Bedke
Der Urologe. Ausg. A|August 24, 2014
[Elective organ and function preservation in ureter and renal pelvis tumors]S Rausch, G Gakis, J Bedke, et al.
Pageof 6